Drug intelligence / Profile preview

SIR8752

Development stage: Preclinical
Lead developer: Sironax

Overview

SIR8752 is an early-stage drug candidate being developed by Sironax for the treatment of immune and inflammatory diseases. Currently in the discovery phase, the specific molecular target and modality of SIR8752 have not been publicly disclosed. Sironax, the developer, focuses on pathways involved in cell death and inflammation to address age-related and degenerative conditions. The program is part of a broader pipeline at Sironax that includes inhibitors of RIPK1 and SARM1, although the specific mechanism for SIR8752 remains proprietary.

Beyond the preview

Go deeper on SIR8752.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR8752.

Explore the full profile